{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T13:43:48Z","timestamp":1759412628439},"reference-count":17,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1016\/j.vaccine.2010.12.008","type":"journal-article","created":{"date-parts":[[2010,12,19]],"date-time":"2010-12-19T04:06:29Z","timestamp":1292731589000},"page":"1180-1184","source":"Crossref","is-referenced-by-count":21,"title":["Spontaneous reporting of adverse events following immunisation against pandemic influenza in Denmark November 2009\u2013March 2010"],"prefix":"10.1016","volume":"29","author":[{"given":"Maja","family":"Folkenberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torbj\u00f6rn","family":"Callr\u00e9us","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Svanstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Palle","family":"Valentiner-Branth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Hviid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.vaccine.2010.12.008_bib0005","first-page":"249","article-title":"New influenza A (H1N1) virus: global epidemiological situation, June 2009","volume":"84","year":"2009","journal-title":"Weekly Epi Rec"},{"key":"10.1016\/j.vaccine.2010.12.008_bib0010","unstructured":"Summary of Product characteristics (SPC) Pandemrix\u00ae: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001206\/WC500049544.pdf [accessed 23 November 2010]."},{"key":"10.1016\/j.vaccine.2010.12.008_bib0015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(09)62133-4","article-title":"Defining the safety profile of pandemic influenza vaccines","volume":"375","author":"Pfeifer","year":"2010","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.vaccine.2010.12.008_bib0020","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.2105\/AJPH.2007.124537","article-title":"Adverse event detection in drug development: recommendations and obligations beyond phase 3","volume":"98","author":"Berlin","year":"2008","journal-title":"Am J Public Health"},{"key":"10.1016\/j.vaccine.2010.12.008_bib0025","unstructured":"European Medicines Agency pandemic influenza (H1N1) website: Authorisation procedures. http:\/\/www.ema.europa.eu\/influenza\/vaccines\/authorisation_procedures.htm [accessed 23 November 2010]."},{"key":"10.1016\/j.vaccine.2010.12.008_bib0030","unstructured":"European Strategy for Influenza A\/H1N1 Vaccine Benefit-Risk Monitoring; October 2009. http:\/\/www.ema.europa.eu\/pdfs\/human\/pandemicinfluenza\/european_strategy.pdf [accessed 23 November 2010]."},{"key":"10.1016\/j.vaccine.2010.12.008_bib0035","unstructured":"Brighton Collaboration: https:\/\/brightoncollaboration.org\/public [accessed 23 novemver 2010]."},{"issue":"8","key":"10.1016\/j.vaccine.2010.12.008_bib0040","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1517\/14712590903066695","article-title":"Prepandemic H5N1 influenza vaccine adjuvated with AS03: a review of the pre-clinical and critical data","volume":"9","author":"Leroux-Roels","year":"2009","journal-title":"Expert Opin Biol Ther"},{"issue":"7","key":"10.1016\/j.vaccine.2010.12.008_bib0045","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1001\/jama.2009.1201","article-title":"Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine","volume":"302","author":"Slade","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2010.12.008_bib0050","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00430-009-0130-9","article-title":"Possible hidden hazards of mass vaccination against new influenza A\/H1N1: have the cardiovascular risks been adequately weight?","volume":"198","author":"Bhakdi","year":"2009","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2010.12.008_bib0055","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1086\/603560","article-title":"Prepandemic immunization for novel influenza viruses, swine flu vaccine, Guillain\u2013Barr\u00e9 syndrome, and the detection of rare severe adverse events","volume":"200","author":"Evans","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2010.12.008_bib0060","unstructured":"Final summary of adverse drug reaction reports in Sweden with Pandemrix through October 2009\u2013mid April 2010. http:\/\/www.lakemedelsverket.se\/upload\/eng-mpa-se\/Pandemrix%20ADRs%20in%20Sweden%2015%20april%202010.pdf [accessed 23 November 2010]."},{"key":"10.1016\/j.vaccine.2010.12.008_bib0065","doi-asserted-by":"crossref","first-page":"5467","DOI":"10.1016\/j.vaccine.2010.05.066","article-title":"Surveillance of adverse events following immunization against pandemic influenza in Slovenia in season 2009\/2010","volume":"28","author":"Kraigher","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.12.008_bib0070","doi-asserted-by":"crossref","first-page":"7248","DOI":"10.1016\/j.vaccine.2010.09.021","article-title":"Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009\u2013January 31, 2010","volume":"28","author":"Vellozzi","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.12.008_bib0075","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0140-6736(10)60154-7","article-title":"The swine flu backlash","volume":"375","author":"Laurance","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2010.12.008_bib0080","first-page":"12","article-title":"WHO \u2018has lost creadibility\u2019 over flu scare","author":"Boseley","year":"2010","journal-title":"The Guardian Weekly April 2"},{"issue":"25","key":"10.1016\/j.vaccine.2010.12.008_bib0085","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1056\/NEJMp0903906","article-title":"The signature features of influenza pandemics\u2014implications for policy","volume":"360","author":"Miller","year":"2009","journal-title":"N Engl J Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10017469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10017469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T00:26:07Z","timestamp":1544055967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X10017469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["S0264410X10017469"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2010.12.008","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2011,2]]}}}